Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44] (S0959804917300850) (10.1016/j.ejca.2017.01.024))

1. Massard, C.
2. Chi, K.N.
3. Castellano, D.
4. de Bono, J.
5. Gravis, G.
6. Dirix, L.
7. Machiels, J.-P.
8. Mita, A.
9. Mellado, B.
10. Turri, S.
11. Maier, J.
12. Csonka, D.
13. Chakravartty, A.
14. Fizazi, K.